These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 17223694)
1. Heat-induced dimerization of BCL-xL through alpha-helix swapping. Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694 [TBL] [Abstract][Full Text] [Related]
2. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577 [TBL] [Abstract][Full Text] [Related]
3. Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Denisov AY; Chen G; Sprules T; Moldoveanu T; Beauparlant P; Gehring K Biochemistry; 2006 Feb; 45(7):2250-6. PubMed ID: 16475813 [TBL] [Abstract][Full Text] [Related]
4. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol. Priyadarshi A; Roy A; Kim KS; Kim EE; Hwang KY Biochem Biophys Res Commun; 2010 Apr; 394(3):515-21. PubMed ID: 20206602 [TBL] [Abstract][Full Text] [Related]
5. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl. Xu H; Tai J; Ye H; Kang CB; Yoon HS Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050 [TBL] [Abstract][Full Text] [Related]
6. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Muchmore SW; Sattler M; Liang H; Meadows RP; Harlan JE; Yoon HS; Nettesheim D; Chang BS; Thompson CB; Wong SL; Ng SL; Fesik SW Nature; 1996 May; 381(6580):335-41. PubMed ID: 8692274 [TBL] [Abstract][Full Text] [Related]
7. Bcl-xL forms two distinct homodimers at non-ionic detergents: implications in the dimerization of Bcl-2 family proteins. Feng Y; Lin Z; Shen X; Chen K; Jiang H; Liu D J Biochem; 2008 Feb; 143(2):243-52. PubMed ID: 18006518 [TBL] [Abstract][Full Text] [Related]
8. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074 [TBL] [Abstract][Full Text] [Related]
9. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
10. The cell death machinery controlled by Bax and Bcl-XL is evolutionarily conserved in Ciona intestinalis. Takada N; Yamaguchi H; Shida K; Terajima D; Satou Y; Kasuya A; Satoh N; Satake M; Wang HG Apoptosis; 2005 Dec; 10(6):1211-20. PubMed ID: 16215691 [TBL] [Abstract][Full Text] [Related]
11. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL. Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295 [TBL] [Abstract][Full Text] [Related]
14. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein. Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970 [TBL] [Abstract][Full Text] [Related]
15. Oligomerization of BH4-truncated Bcl-x(L) in solution. Wang Y; Cao R; Liu D; Chervin A; Yuan J; An J; Huang Z Biochem Biophys Res Commun; 2007 Oct; 361(4):1006-11. PubMed ID: 17692289 [TBL] [Abstract][Full Text] [Related]
16. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL. Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284 [TBL] [Abstract][Full Text] [Related]
17. A new assay for the discovery of Bcl-XL inhibitors. Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143 [TBL] [Abstract][Full Text] [Related]
18. Behavior of solvent-exposed hydrophobic groove in the anti-apoptotic Bcl-XL protein: clues for its ability to bind diverse BH3 ligands from MD simulations. Lama D; Modi V; Sankararamakrishnan R PLoS One; 2013; 8(2):e54397. PubMed ID: 23468841 [TBL] [Abstract][Full Text] [Related]
19. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. Yao Y; Bobkov AA; Plesniak LA; Marassi FM Biochemistry; 2009 Sep; 48(36):8704-11. PubMed ID: 19670908 [TBL] [Abstract][Full Text] [Related]
20. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]